Moneycontrol Be a Pro
Get App
you are here: HomeNewsBusiness
Last Updated : Nov 15, 2019 06:54 PM IST | Source: PTI

Unichem Labs gets USFDA nod to market anxiety disorder tablets

The company has received abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration (USFDA) to market its Buspirone Hydrochloride tablets USP, in the strengths of 5 mg, 10 mg, 15 mg, and 30 mg, Unichem Laboratories said in a BSE filing.

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Unichem Laboratories on Friday said it has received approval from the US health regulator to market its generic Buspirone Hydrochloride tablets used for management of anxiety disorders.

The company has received abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration (USFDA) to market its Buspirone Hydrochloride tablets USP, in the strengths of 5 mg, 10 mg, 15 mg, and 30 mg, Unichem Laboratories said in a BSE filing.

The company's tablets are a generic version of Bristol-Myers Squibb Company's Buspar tablets in the same strengths, it added.

Close

The product will be commercialised from the company's Ghaziabad plant, Unichem said.

Buspirone Hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety, it added.

Shares of Unichem Laboratories closed at Rs 149.85 per scrip on BSE, up 5.16 per cent from its previous close.

LIVE NOW... Video series on How to Double Your Monthly Income... where Rahul Shah, Ex-Swiss Investment Banker and one of India's leading experts on wealth building, reveals his secret strategies for the first time ever. Register here to watch it for FREE.
First Published on Nov 15, 2019 06:40 pm
Loading...
Follow us on
Available On